Paul Wakim

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies

Gina A. Montealegre Sanchez, Adam Reinhardt, Suzanne Ramsey et al. · Journal of Clinical Investigation · 2018 · 521 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Long‐term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi‐site trial

Yih‐Ing Hser, Elizabeth Evans, David Huang et al. · Addiction · 2015 · 216 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end‐points in clinical trials

Dennis M. Donovan, George E. Bigelow, Gregory S. Brigham et al. · Addiction · 2011 · 205 citations

Medicine, Behavioral Sciences, Pharmacology +12

Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels

Peter J. Schmidt, Pedro E. Martinez, Lynnette K. Nieman et al. · American Journal of Psychiatry · 2017 · 204 citations · Full text

Medicine, Endocrinology, Psychiatry +17

Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients

Hanna Kim, Kristina M. Brooks, Cheng Cai Tang et al. · Clinical Pharmacology & Therapeutics · 2017 · 131 citations

Pharmacy, Pharmacokinetics, Pharmacology +17